400 you need to find from somewhere Payday loans Why is a payday loan right for you
Home >> Milestones
1951:
  • Shri Indravadan Modi thinks of starting a Pharmaceutical unit
1952:
  • On March 13th, Cadila starts production
1967:
  • Cadila shifts to its own factory premises with operations full-fledged spanning Production, Marketing, R&D
1970:
  • Shri IA Modi represents the Indian Pharma industry and plays a pivotal role in shaping the Patents Act, 1970
1982:
  • Karnavati Engineering Limited (KEL), Kadi the machinery-manufacturing arm of Cadila, commences operations
1986:
  • Shri IA Modi plays a major role in shaping the 1986 Drug Policy
1992:
  • Tissue Culture Laboratory commences operation at Hirapur near Ahmedabad
1995:
  • Cadila gets restructured as Cadila Pharmaceuticals Ltd.
1997:
  • GUSSACON(Gujarat State Surgeons Conference) felicitates Shri IA Modi at its 23rd Annual Conference for his outstanding contribution to the industry
1999:
  • Cadila Pharmaceuticals Ltd. ventures in the US market by establishing CPL Inc.
2000:
  1. Cadila Pharmaceuticals moves to an ultra-modern Corporate Campus at Bhat, Ahmedabad
  2. Cadila Pharmaceuticals ties-up with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi and Talwar Research Foundation, New Delhi.
  3. Cadila Pharmaceuticals introduces World’s First IMMUVAC, a unique Immunomodulator
2001:
  • Cadila Pharmaceuticals launches NEVA HIV - World's First whole blood Rapid HIV detection kit
2002:
  1. Cadila Pharmaceuticals ventures in Japan and sets up Kadera Yakuhin Ltd.
  2. Cadila Pharmaceuticals becomes India's First indigenous manufacturer of natural Streptokinase – STPase
2003:
  • Shri IA Modi receives the Express Pharma Pulse Lifetime Contribution Award
2004:
  1. Cadila Pharmaceuticals launches world's first Parenteral Formulation of Rabeprazole (Rabeloc I.V.)
  2. Cadila Pharmaceuticals submits first IND (Investigational New Drug) with the USFDA for pulmonary tuberculosis.
2005:
  1. KEL’s new production line becomes operational and dispatches first machinery to USA.
  2. Shri IA Modi receives a Lifetime Achievement Award by Gujarat Chamber of Commerce and Industry for his outstanding contribution to the Industry and society.
  3. Cadila Pharmaceuticals publishes and presents a series of scientific papers on Immuvac, Itza and Rabeloc I.V. at UEGW (United European Gastroenterology Week, Prague), APDW (Asia Pacific Digestive Week, Beijing), AGW (Australian Gastroenterology Week), DDW (Digestive Diseases Week, Chicago, USA), ASCO (American Society of Clinical Oncology), WCOG (World Congress of Gastro).
2006:
  1. Cadila Pharmaceuticals acquires Pfizer's API facility at Ankleshwar
  2. The formulation facility at Samba near Jammu, becomes operational
  3. Cadila Pharmaceuticals enters into a joint venture with Apollo Hospitals Group to manage Apollo Hospitals, Ahmedabad
  4. Cadila Pharmaceuticals submits four more INDs (Investigational New Drug) with the USFDA for Lung Cancer, Prostrate cancer, Bladder Cancer and Melanoma.
2007:
  1. ‘Divya Bhaskar’ honours Shri IA Modi with Lifetime Achievement Award
  2. As part of efforts to prevent lifestyle diseases; Cadila Pharmaceuticals commences large clinical trials aimed at prevention of Cardiovascular disease and stroke by using an innovative polypill
  3. Cadila Pharmaceuticals inaugurates its first overseas manufacturing facility in Ethiopia, Cadila Pharmaceuticals (Ethiopia) PLC.
2008:
  1. Shri IA Modi figures in the 'Gujarat Glories annual power list of 50 businessmen’
  2. Shri IA Modi features in 'Power 100: Eminent Personalities of Gujarat'
  3. Indian Pharmaceutical Association confers Ramanbhai Patel Foundation Lifetime Achievement Award to Shri IA Modi
  4. Cadila Pharmaceuticals with StemCyte Inc. USA and Apollo Hospitals Group forms a JV, StemCyte India, for Umbilical Cord Blood Stem Cells Banking and Research
  5. Dholka manufacturing facility receives renewal of regulatory approval from MCC, South Africa
  6. Cadila Pharmaceuticals receives financial assistance from New Millennium Indian Technology Leadership Initiative (NMITLI) to develop novel treatment for Sepsis management.
2009:
  1. Cadila Pharmaceuticals features as one of the 'Most Trusted Companies of 2008' by Sara Media and Zee Business
  2. Cadila Pharmaceuticals unveils world’s first Polycap, which reduces the risk of heart disease by 68% and stroke by 48%
  3. Cadila Pharmaceuticals acquires a significant stake in Novavax Inc., USA; a clinical-stage biopharmaceutical company
  4. Announces CPL Biologicals, a joint venture with Novavax Inc. USA, to develop and produce vaccines based on virus-like-particle (VLP) vaccine technology
  5. TIPS, The Indian Polycap Study, becomes the first Indian publication to feature in The Lancet (Medical Journal)
  6. Cadila Pharmaceuticals launches POLYCAP, the combination drug for the prevention of CVDs
  7. Launches the revolutionary Risorine, world’s first anti TB- drug with bio-enhancer which is an outcome of Public Private Partnership between RRL Jammu and Cadila Pharmaceuticals
  8. Dholka manufacturing facility receives regulatory approval from INVIMA, Columbia
  9. Dr Rajiv Modi leads industrial delegation from Gujarat to Japan as part of VGGIS, to strengthen the business ties between the two countries
  10. Dr Rajiv Modi becomes youngest Fellow of National Associates of Engineers
2010:
  1. State-of-the-art Vaccine manufacturing facility of CPL Biologicals comes up at Dholka near Ahmedabad, Gujarat
  2. Cadila Pharmaceuticals Limited receives prestigious Wellcome Trust Award under the new R & D for Affordable Healthcare in India initiative to support a phase III clinical trial of Polycap
  3. Cadila Pharmaceuticals receives financial assistance from New Millennium Indian Technology Leadership Initiative (NMITLI) to develop novel treatment for diabetes drug.
2011:
  1. Ethiopia manufacturing facility receives WHO-cGMP certification, the only facility in the region
  2. Dholka manufacturing facility receives Pre Qualification approval from WHO, Geneva
  3. Dr Rajiv Modi speaks on the topic “Challenges Relevant to Vaccine Virus Selection - Emerging Market Perspective” at the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection, Geneva
2012:
  1. Cadila Pharmaceuticals announces a strategic alliance with Swedish Bactiguard, world-leaders in clinically proven solutions for preventing hospital-acquired infections
  2. CPL Biologicals and the International Centre for Genetic Engineering and Biotechnology enters into a new collaboration to develop novel multi-stage Malaria Vaccine in India based on proprietary VPL vaccine technology of Novavax
  3. Cadila Pharmaceuticals completes TIPS II for Cardiovascular Diseases
  4. CII Gujarat State Council elects Dr Rajiv Modi as Vice Chairman
  5. Cadila Pharmaceuticals initiates multinational TIPS III for treatment of Cardiovascular diseases covering twelve countries
  6. Cadila Pharmaceuticals submits tenth ANDA with USFDA, first being submitted in 2009
  7. Dholka manufacturing facility receives regulatory approval from MHRA, UK and TGA, Australia
2013:
  1. CII Gujarat State Council elects Dr Rajiv Modi as Chairman
  2. Cadila Pharmaceuticals enters into a strategic collaboration with Pergamum AB, Sweden, to develop a novel treatment of infections with a unique targeting mechanism clearly distinguished from classical antibiotics.
  3. Dholka formulation manufacturing facility receives USFDA certification
  4. Dholka manufacturing facility receives regulatory approval from EU GMP-Latvia
  5. Cadila Pharmaceuticals files 38th USDMFs, first being filed in 2007
  6. Cadila Pharmaceuticals files 22nd API EDMF (EUDMF) for European markets